logo-loader
RNS
viewHikma Pharmaceuticals Plc

Director/PDMR Shareholding

/**/ .s{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.s{}p.ao{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 13.2pt; margin-left: 0cm; margin-right: 0cm; margin-top: 13.2pt; text-align: center; text-decoration: underline}span.am{font-size:12.0pt;font-family:"Times New Roman","serif"}p.ap{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 13.2pt; margin-left: 0cm; margin-right: 0cm; margin-top: 13.2pt; text-align: justify}table.aq{border:solid windowtext 1.0pt}tr.af{page-break-inside:avoid}td.ah{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm}p.ar{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:5.65pt;line-height:normal}span.aj{font-size:12.0pt; font-family:"Times New Roman","serif"} td.ag{width:432.6pt;border:solid windowtext 1.0pt; padding:0cm 0cm 0cm 0cm}tr.ab{page-break-inside:avoid;height:30.95pt}td.ae{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm; height:30.95pt}td.ad{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:30.95pt}td.ac{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:30.95pt}td.aa{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm}td.z{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm}tr.v{page-break-inside:avoid;height:37.4pt}td.y{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm; height:37.4pt}td.x{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:37.4pt} td.w{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:37.4pt}p.as{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:13.2pt;margin-right:0cm;margin-bottom: 13.2pt;margin-left:0cm;line-height:normal} /**/
RNS Number : 5610L
Hikma Pharmaceuticals Plc
06 September 2019
 

Notification and public disclosure of transactions by person discharging managerial responsibilities

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Disposal of 150,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC by Banque Lombard Odier & Cie SA

c)

Price(s) and volume(s)

Price(s): £20.56

Volume(s): 49,826

Price(s): £19.85

Volume(s): 25,000

Price(s): £19.82

Volume(s): 25,000

Price(s): £19.84

Volume(s): 25,000

Price(s): £19.82

Volume(s): 25,174

d)

Aggregated information

Aggregated volume: 150,000

Price: £20.07

Total: £3,011,121

e)

Date of the transaction

4 and 6 September 2019

f)

Place of the transaction

London Stock Exchange (XLON)

Peter Speirs, Company Secretary, Responsible for releasing this announcement

6 September 2019


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHBSGDCXDGBGCL

Quick facts: Hikma Pharmaceuticals Plc

Price: 1902

Market: AIM
Market Cap: £46.09 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE